Chronic myelogenous leukemia with e13a3 (b2a3) type of BCR‐ABL transcript having a DNA breakpoint between ABL exons a2 and a3
- 17 November 2003
- journal article
- case report
- Published by Wiley in American Journal of Hematology
- Vol. 74 (4), 268-272
- https://doi.org/10.1002/ajh.10429
Abstract
We describe a patient with chronic myelogenous leukemia (CML), in whom the DNA breakpoint in the BCR‐ABL fusion gene was determined to result in a rare e13a3 (b2a3) transcript. The breakpoint in BCR was intron 13, which was 30 bp downstream from exon 13, and the breakpoint in ABL was intron 2, and was 46 bp downstream from exon a2. This case conforms to the mechanism of DNA breakage occurring within ABL intron 2, but not at 5′ to ABL exon a2. With our review of this case and the literature, it seems that CML with the BCR‐a3 fusion product is associated with a low proportion of circulating immature cells, mild or lack of splenomegaly, slow progressiveness, rather resistance to IFN‐α, and good response to imatinib mesylate. This is the first report of BCR‐a3‐type CML in which the exact DNA breakpoint was identified and located between exons a2 and a3 of the ABL gene. Am. J. Hematol. 74:268–272, 2003.This publication has 11 references indexed in Scilit:
- CML with an e1a3 BCR-ABL fusion: rare, benign, and a potential diagnostic pitfallBlood, 2002
- E1A3 as a unique, naturally occurring BCR–ABL transcript in an indolent case of chronic myeloid leukaemiaBritish Journal of Haematology, 2001
- Nonrandom distribution of interspersed repeat elements in the BCR and ABL1 genes and its relation to breakpoint cluster regions.Genes, Chromosomes and Cancer, 2001
- Are aberrant BCR -ABL transcripts more common than previously thought?British Journal of Haematology, 2000
- Lack of SH3 domain does not imply a more severe clinical course in Ph+ chronic myeloid leukemia patientsBlood, 2000
- Bcr-Abl with an SH3 Deletion Retains the Ability To Induce a Myeloproliferative Disease in Mice, yet c-Abl Activated by an SH3 Deletion Induces Only Lymphoid MalignancyMolecular and Cellular Biology, 1999
- Concamitant expression of the rare E1/A3 and B2/A3 types of BCR/ABL transcript in a chronic myeloid leukemia (CML) patientLeukemia, 1999
- Signal Transducer and Activator of Transcription (STAT)5 Activation by BCR/ABL Is Dependent on Intact Src Homology (SH)3 and SH2 Domains of BCR/ABL and Is Required for LeukemogenesisThe Journal of Experimental Medicine, 1999
- A new case of chronic myeloid leukemia (CML) in myeloid blast crisis with an atypical (b3/a3) junction of the BCR/ABL geneLeukemia, 1998
- 2 BCR-ABL gene variantsBailliere's Clinical Haematology, 1997